READ: Featured Drug Insights: September 2025 - Prime Therapeutics
READ: Featured Drug Insights: September 2025
Your source for all Prime Therapeutics' September 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for September 2025 will keep you informed on what’s trending now and trending clinical topics.
Released Sept. 22, 2025
FDA drug recalls
Cyclobenzaprine HCl Tablets 10 mg
Unichem has voluntarily recalled one lot of Cyclobenzaprine HCl Tablets 10 mg (NDC 29300-0415-19) to the consumer level. The cyclobenzaprine 10 mg (90-count) label was inadvertently placed on a bottle containing meloxicam 7.5 mg tablets.
Released Sept. 16, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are etuvetidigene autotemcel, celmidsogene lanparvovec and more.
Released Sept. 17, 2025
FDA Decisions Expected: October 2025
A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers semaglutide (oral), aflibercept, golimumab and more.
Released Sept. 19, 2025
Featuring commentary by Abby Kim, PharmD, BCOP, on developments in the oncology space, this installment covers immunoglobulin use in multiple myeloma (MM), a rare hematologic malignancy representing roughly 1-2% of all cancers occuring in individuals aged 65 or older.
Released Sept. 19, 2025
Expert Clinical Network Insights: September 2025
Committed to keeping you informed on the latest specialty drug insights from leading experts, this newsletter features delandistrogene moxeparvovec-rokl (Elevidys), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD).
Released Sept. 22, 2025
Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features Clemidsogene lanparvovec (RGX-121), a vector gene therapy designed to treat Mucopolysaccharidosis II (MPS II), also known as Hunter Syndrome.
Released Sept. 30, 2025
Trending Topics & Drug Approvals: September 2025
We've combined Clinical Highlights and Drug Approvals into this new, monthly publication, which covers the latest specialty and traditional drug approvals. The latest edition features an update on safety label changes for products containing acetaminophen (Tylenol, other brand names).
Looking for previous 2025 drug insights publications?
Simply click on the month to access past editions of our drug insights.
All brand names are property of their respective owners.